5.1 - Cartilage Biology and Osteoarthritis Flashcards

1
Q

What is osteoarthritis?

A
  • disease of the whole joint which involves the loss of articular cartilage
  • affects cartilage, soft tissue and bone
  • can eventually lead to joint failure
  • commonest form of arthritis, numbers rising
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference between normal articular cartilage and chondral defect?

A
  • normal arthroscopy - you can see the two surfaces of the joints, articular cartilage
  • articular cartilage is also known as hyaline cartilage
  • smooth, moony white, deforms when probed but bounces back, resilient, tough, designed to take load
  • chondral defect - raggedy edge (lose smooth, moony white), pink bone
  • can give rise to pain and OA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does normal articular (hyaline) cartilage look like microscopically?

A
  • toluidine blue stain - proteoglycans in ECM stained blue
  • little spots = articular chondrocytes - the only cell in articular cartilage
  • bottom = bone - calcified, tide mark
  • bone –> deep/radial zone –> intermediate/transitional zone –> superficial zone
  • deep zone: bone-like, chondrocytes are stacking, lot of proteoglycans
  • intermediate zone: chondrocytes more widely spaced, more round
  • superficial zone: flatter chondrocytes running parallel to articular cartilage surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does healthy cartilage look like?

A
  • proteoglycan (mainly aggrecan) - proteins and mucopolysaccharide chains - combination of protein and carbohydrate
  • proteoglycan molecules are big
  • they have negative charges = pull water into articular cartilage –> resilient and resists compression
  • type II collagen fibrils - architecture and inherent tensile strength
  • water molecules pulled in then held as collagen constraining the shape of the cartilage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the chondrocyte?

A
  • only cell in cartilage
  • makes up <5% of the tissue
  • produces and degrades the articular cartilage matrix arounds its ECM
  • highly metabolically active
  • exist in relative hypoxia - no blood vessels around
  • interactions with ECM - growth factors, receive mechano-transduction signals from matrix
  • no cell division after adolescence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is type II collagen and collagenases?

A
  • type II collagen is the articular cartilage collagen
  • metalloproteinase - MMP-1, MMP-8, MMP-13 are collagenases
  • cleavage is 3/4 way along the collagen molecule
  • other molecules can also act as collagenases e.g. cathepsin K
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is aggrecan and aggrecanases?

A
  • protein stems with three globular domains - G1, G2, G3
  • side of backbone has mucopolysaccharide chains - chondroitin sulfate and keratin sulfate chains - highly -ve charged = pulls in water and holds it
  • lots of these molecules join on to sugar backbone - hyaluronan chain
  • two types of enzymes break down aggrecan at specific points:
  • matrix metalloproteinases e.g. MMP-3 (a stromelysin)
  • aggrecanases e.g. ADAMTS-4&5
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are anabolic and anti-catabolic factors for articular cartilage in the joint?

A
  • stop the breakdown of cartilage

Intrinsic:

  • TIMPs (tissue inhibitor of metalloproteinases) 1-4
  • growth factors e.g. fibroblast growth factor (FGF-2), insulin-like growth factor (IGF), transforming growth factor (TGF-B), activin A

Extrinsic:

  • hormones e.g. testosterone, oestrogen
  • some drugs e.g. FGF-18
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why does matrix loss occur?

A
  • excessive degradation - too much breakdown from these metalloproteinases
  • reduced anabolism/repair
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How does mechanical load affect cartilage?

A
  • cartilage/chondrocytes need mechanical load to maintain cartilage thickness and turnover - without this, there is cartilage atrophy e.g. in stroke patients
  • compared to standing, the load going through the tibiofemoral joint of your knee increases:
  • walking - 2-6x body weight
  • jumping - 7-9x body weight
  • running - 3-8x body weight
  • climbing stairs - 3-10x body weight
  • if you increase your weight by 5kg, your knees will support 15-30kg more pressure on walking
  • load is always greater through the medial compartment of the knee
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the pathogenesis of osteoarthritis?

A
  • many tissues are affected in the synovial joint in OA:
  • articular cartilage
  • subchondral bone
  • ligament and soft tissue
  • inflammation, repair and remodelling, pain pathways are important
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the molecular changes that precede structural changes in OA?

A
  • excessive degradation
  • proteoglycan is fragmented by aggrecanases
  • collagen broken down by collagenases
  • water - initial swelling of matrix, then lost
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the pathology of OA?

A
  • early OA - loss of proteoglycans in superficial zone of articular cartilage
  • there is then fibrillation of surface - loss of articular cartilage integrity, more loss of proteoglycan staining
  • established OA - fissuring - loss of integrity going down into the cartilage rather than just superficial
  • partial and full thickness loss, osteophytes (new bits of bone emanated that are generated as part of healing attempts), bone cysts, synovial inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the risk factors for OA development?

A
  • age
  • obesity - increased mechanical load, systemic inflammation
  • mechanical factors e.g. joint injury, malalignment
  • family history
  • chondrodysplasias (e.g. defects in type II collagen) e.g. Stickler syndrome
  • other medical conditions e.g. haemochromatosis
  • secondary joint damage due to inflammatory arthropathies e.g. rheumatoid arthritis
  • around 100 genetic variants associated with OA risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is post-traumatic OA?

A
  • OA following injury
  • a model for understanding early mechanisms in OA
  • 50% with meniscal or anterior cruciate ligament tear will develop OA within 5-10 years
  • individuals are generally young (30s-40s)
  • inflammatory response can be seen in the joint response to joint trauma (e.g. MMP-3, IL-6 in synovial fluid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the evidence for mechanical factors in OA?

A
  • destabilising joint injuries increase risk of OA
  • intra-articular fracture increases the risk of OA
  • occupational examples of increased use - ‘Foundry workers’ elbow’; ‘Coal miners’ back’
  • mal-aligned joints get OA e.g. varus malignment and medial joint OA
  • paralysed joints are usually protected from OA
17
Q

What does meniscal destabilisation result in?

A

Progressive articular cartilage damage

18
Q

What kind of process is cartilage loss after injury?

A
  • active biological process
  • depends on an aggrecanase
  • not just attrition/wear and tear, it is active
19
Q

What is a simple hypothesis for OA?

A
  • normal joint, abnormal load OR abnormal joint, normal load –> mechanical tissue injury –> tissue damage/inadequate repair –> symptomatic OA
20
Q

How does incidence and prevalence of OA change?

A
  • increases with age and is greater in women
  • not all OA progresses - some improves/gets better
21
Q

How is OA diagnosed clinically?

A
  • diagnosis is often clinical
  • joint pain (typically on activity)
  • stiffness typically <30 mins
  • loss of function
  • examination findings: crepitus, bony deformity and joint line tenderness, loss of normal range, warmth/effusion
22
Q

How is OA diagnosed through X-rays?

A
  • X-rays - not necessary to diagnose but can be useful for staging and treatment planning
  • can show diagnostic changes but these may be absent early in disease: osteophytes, joint space narrowing, subchondral sclerosis, bone cysts
23
Q

How is OA diagnosed through blood tests?

A
  • none in routine clinical use which diagnose OA
  • often normal but can be a low ‘inflammatory response’ e.g. slight increase in CRP
  • tests for rheumatoid arthritis (where appropriate) are negative
  • other blood tests may be relevant to exclude secondary causes e.g. iron, calcium, PTH, glucose
24
Q

What is knee osteoarthritis?

A
  • knee is the most commonly affected site
  • symptomatic disease more common in women
  • women have a lifetime risk of 45% of knee OA
25
Q

What is hand osteoarthritis?

A
  • hand OA very common - 26% women and 13% men aged 70
  • joints - distal interphalangeal and proximal interphalangeal, followed by the base of the thumb
  • base of thumb or multiple joint interphalangeal joint disease particularly affects hand function
  • often around menopause - symptoms may settle after 2-5 years
  • Heberden’s nodes are common - bumps in fingers
26
Q

How can OA be managed?

A
  • exercise e.g. local muscle strengthening, general aerobic fitness
  • weight management
  • information and support
  • some drugs can be used for pain relief
  • manual therapy
  • devices e.g. walking aids
  • joint replacement
27
Q

What are surgical options for OA?

A
  • total joint replacement / arthroplasty (hip or knee) is a highly effective treatment (best results when pain high, function poor, over 60, end stage radiographic disease)
  • uni-compartmental replacement for the knee is possible
  • trapeziectomy (removal of a thumb bone) is a good surgical treatment for base of thumb OA
  • other surgical treatments such as arthroscopy are not evidence based
28
Q

What are new treatments for OA aiming for?

A
  • symptom modification (SyMOAD - symptom modifying OA drug) - treat pain and improve function
  • slow/prevent early disease (DMOAD - disease modifying OA drug)
  • complex relationship between pain and structure in OA
  • the right drug targets (efficacy and safety), the right population, the right outcome measures